AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02949622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program
Description: The intervention is structured as follows:~Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)
Study NCT03118375 — intervention group
Intervention type: DEVICE
Intervention: super-power BAHA processor
Description: The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
Study NCT04191070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infrazygomatic miniscrew
Description: class II correction by distalization using infrazygomatic crest miniscrew
Study NCT02949622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
Study NCT03512587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized quantum sonotherapy
Description: Quantum sonotherapy is an alternative non-pharmacological treatment that effects a molecular reorganization that occurs after the sound stimulus. The audible words and their waves have the ability to generate vibrations and stimulate the psycho-neuro-endocrine chain, independent of the semantic meaning of the words. It is an alternative therapy that uses non-musical sound waves.
Study NCT03512587 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Headphones will be place in patients without playing quantum sonotherapy
Study NCT03578419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Small-Volume Blood Collection Tubes
Description: Small-volume vacuum (\< 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
Study NCT03578419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-Volume Blood Collection Tubes
Description: Standard-volume (≥ 4 mL) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and serum blood collection tubes.
Study NCT04191070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zygomatic miniplate
Description: class II correction by distalization using zygomatic miniplate
Study NCT04152785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information regarding GHG and/or nutrition
Description: Participants will have to select a meal from a menu.
Study NCT01670188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pneumatic SCD - VenaFlow System (DJO Global)
Study NCT00836914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL-101
Description: CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
Study NCT00836914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered orally BID for 7 days
Study NCT06210737 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: 3 doses of PCV13 intramuscularly at Months 0, 2, and 4 and a booster dose at Month 10
Study NCT06210737 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: 2 doses of PCV13, and a booster dose
Study NCT06210737 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: 2 doses of PCV13
Study NCT06210737 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PCV13
Description: single dose of PCV13
Study NCT04152785 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information regarding GHG and/or nutrition
Description: Participants will have to select a meal from a menu.
Study NCT04544228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block Technique
Description: The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
Study NCT04544228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block Technique
Description: The patient will be placed in Lateral Decubitus with a surgical side upwards with arm abduction. A linear ultrasound transducer (6-13 MHz) will be placed on the patient's midaxillary line in the transverse plane, at the level of the fifth rib, with the indicator oriented toward the operator's left. With the rib, pleural line, and overlying serratus anterior and latissimus dorsi muscles visualized, local infiltration of the skin and subcutaneous tissue will be applied by 2-3ml of lidocaine 2%. Then, using ultrasound guidance, A 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the fifth rib. The expecting depth for this block is 1-4 cm. After aspiration, injection 30ml local anesthetic mixture will be injected anteriorly to the rib and deep to the serratus anterior muscle.
Study NCT02702739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks
Description: Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
Study NCT01954771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMBG
Description: Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.~SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
Study NCT01954771 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGMS
Description: In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
Study NCT02896439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurophysiological MONITORING
Description: The neurophysiology team perform:~* Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.~* Acquisition of data by the machine and the software Protektor® (Natus) in the following format:~A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:~* Establishment of a spacer or forceps in the greater or lesser sciatic notch~* Traction layout~For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:~* At the end of the incision~* On the establishment of a spacer or forceps in the greater or lesser sciatic notch~* When towing layout~* At the end of the intervention
Study NCT04544228 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes.
Study NCT02775877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02775877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study NCT04544228 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Induction of general anaesthesia will be performed using a regimen of IV 2 μg/kg fentanyl and propofol IV 2 mg /kg. Tracheal intubation will be facilitated using 0.5 mg/kg IV of rocuronium.~Anaesthesia will be maintained with inhaled sevoflurane 2-2.5% in oxygen enriched air (FiO2=0.5). Maintenance doses of rocuronium 0.1 m\\kg will be provided every 30 minutes.~The residual neuromuscular blockade will be reversed using neostigmine (0.05 mg/kg) and atropine (0.02 mg/kg), and extubation will be performed after complete recovery of the airway reflexes.
Study NCT02775877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clomiphene
Study NCT02775877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMG
Study NCT03242187 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-anal total mesorectal excision(TaTME)
Description: Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
Study NCT03242187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lap. TME
Description: Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
Study NCT02590874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
Study NCT02590874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
Study NCT00477607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid
Description: Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
Study NCT00477607 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiology
Description: otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
Study NCT00477607 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Audiology
Description: otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
Study NCT00477607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
Study NCT00477607 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
Study NCT00477607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
Study NCT03792529 — intervention group
Intervention type: OTHER
Intervention: detect gene mutations of ctDNA and ctRNA
Description: Samples were collected from patients at baseline, during therapy and after disease progression, and gene mutations of ctDNA and ctRNA were detected in the samples.
Study NCT02144207 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Study NCT00645281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine extended release
Description: Tolterodine ER capsule 4 mg daily for 12 weeks
Study NCT03254212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titration of nocturnal oxygen needs to prevent desaturations
Description: Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to > 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to \< 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
Study NCT03786692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arm A
Description: Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab
Study NCT03786692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arm B
Description: Carboplatin + Pemetrexed + Bevacizumab
Study NCT02920541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 055746
Description: S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
Study NCT03806231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Outpatient Dinoprostone 10mg
Description: Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women randomized to the outpatient cervical ripening group will be administered the drug prior to their induction and discharged after monitoring and physician approval. They will return for their schedule induction.
Study NCT03806231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Dinoprostone 10 mg
Description: Dinoprostone (10 mg) is a vaginal insert approved to start and/or continue the ripening of the cervix in pregnant women who are at or near the time of delivery and in whom there is a medical reason for inducing (bringing on) labor. Women who are randomized to the inpatient cervical ripening group will be administered the drug prior to their induction and remain hospitalized.
Study NCT00520481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-A12 (Cixutumumab)
Description: 10 mg/kg i.v. infusion over 1 hour every 2 weeks or 20 mg/kg i.v. infusion over 1 hour every 3 weeks.
Study NCT00102141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Description: Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
Study NCT00102141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Description: Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
Study NCT00102141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Description: Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
Study NCT00102141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
Description: 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
Study NCT00102141 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, given as tablets orally once daily in the morning for 8 weeks
Study NCT00508287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-686117
Description: Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
Study NCT04544228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine +ketamine
Description: 30 ml bupivacaine 0.25% + 1 ml ketamine (50mg) in Serratus Anterior Plane Block.
Study NCT00508287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Byetta
Description: Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
Study NCT00508287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
Study NCT00074997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intravenous infusion of placebo.
Study NCT00074997 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: OZ1
Description: Single intravenous infusion of OZ1.
Study NCT00074997 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CD34+ cells
Description: Autologous CD34+ cells.
Study NCT00074997 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: CD34+ cells
Description: Autologous CD34+ cells.
Study NCT04206176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 45mg twice daily per oral administration
Study NCT04046848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCTA101
Description: OCTA101 is composed of OCTA8 (human-cl rhFVIII - Nuwiq Intermediate 2 Q-Eluate) and OCTA12 (recombinant human VWF fragment dimer).
Study NCT03149289 — intervention group
Intervention type: DRUG
Intervention: Antiviral drugs
Description: sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
Study NCT02733341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cangrelor
Study NCT02733341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Study NCT04146675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRICOT JERSEY VANISE DOUBLE FACE
Description: Short sleeve t-shirt : TRICOT JERSEY VANISE DOUBLE FACE  THERMOLACTYL EVOLUTION  with ceramic fibers.~A Tinetti test will be performed while wearing the T-shirt, as well as an evaluation of the equilibration on posturography platform under static conditions and an assessment of dynamic equilibrium and locomotion in motion analysis.
Study NCT04146675 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TRICOT JERSEY SIMPLE
Description: Short sleeve t-shirt : TRICOT JERSEY SIMPLE The comparator T-shirt has the same weight, the same appearance, and will be used by patients in the same way and under the same conditions as the T-shirt with ceramic fibers.
Study NCT04437875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac Lyo
Description: adenoviral-based vaccine against SARS-CoV-2
Study NCT02091375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P 20 mg/kg/day Dose
Description: GWP42003-P was an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) dissolved in the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT02091375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo oral solution contained the excipients, sesame oil and anhydrous ethanol (79 mg/mL), with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL).
Study NCT00989456 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self management education programme
Description: The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.~After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh.
Study NCT00989456 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise only
Description: 6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.